Weekly - IPQ.org
Home Weekly


At the Joint Pharmaceutical Analysis Group (JPAG) conference on APIs and excipients held in London in late March, MHRA Lead Senior GMDP Inspector Trevor Watson shared his insights on current regulatory expectations and common inspection findings. He discussed: ● relevant UK and EU legislation for APIs ● inspection of API manufacturers ● API inspection findings between 2021-2023 ● GMP deficiency themes ● inspections of UK and overseas dosage form manufacturers ● common deficiencies in control of starting materials, and ● MHRA compliance referral processes.

At the DIA Europe Conference, held in Brussels in mid-March, African Medicines Regulatory Harmonization (AMRH) Initiative Head Chimwemwe Chamdimba discussed: ● the background of the African Medicines Agency and the foundational role of the AMRH ● AMA key functions and current status ● ongoing AMRH technical support to the AMA ● continental processes, standards and guidelines, and ● reliance and regulatory system strengthening.


At the April 2024 USP Workshop on Peptide and Oligonucleotide Therapeutics, CDER OPQ Senior Pharmaceutical Quality Assessor Katharine Duncan presented on the agency’s CMC regulatory experiences and expectations for peptides. After an introduction to the product class, she explored the elements of a robust control strategy for peptide therapeutics, including: ● manufacturing process controls ● the characterization of peptides and their impurities ● specification setting and testing, and ● stability studies.

At the opening session of the 2024 USP peptide/oligo workshop, held at USP’s Rockville, Maryland headquarters in April, FDA Office of Pharmaceutical Quality (OPQ) Senior Pharmaceutical Quality Assessor Lawrence Perez discussed the CMC challenges the agency has been seeing in reviewing synthetic oligonucleotide therapeutics. His presentation covered: ● defining synthetic oligos, and the different classes that have been approved ● the specification of the API’s identity, purity, and assay, and ● manufacturing issues, including starting materials, API sameness for generics, and platform technologies.

During a WHO townhall session at the DIA Europe Conference, held in Brussels in mid-March, leaders from WHO and EMA explored the role the new WHO Listed Authorities (WLA) initiative will play in WHO’s global regulatory capacity strengthening efforts. Participants in the session included: ● WHO Regulatory Convergence and Networks Team Lead Samvel Azatyan, who introduced and moderated the session ● WHO Regulatory Systems Strengthening Team Lead Alireza Khadem Broojerdi, who spoke about the objectives and progress of the WLA initiative ● WHO Facilitated Product Introduction Team Lead Marie Valentin, who continued the discussion of WLA as a pathway to regulatory efficiency and reliance, and ● EMA International Department Head Martin Harvey Allchurch, who discussed EMA/EU support for and engagement with the WHO regulatory strengthening, collaboration and reliance efforts.

At the CDMO Workshop that followed the PDA Annual Meeting in late March 2024, FDA CBER Office of Cellular Therapy and Human Tissue CMC Deputy Director Steven Oh shared his insights on sponsor/CDMO relationships for CGTs and how they can be strengthened. He reviewed: ● the challenges in the manufacturing, logistics, and development spaces for CGTs, as well as ● actions that can be taken by the sponsors, CDMO’s, and collaboratively to address them.

At the DIA Europe Conference, held in Brussels in mid-March, MHRA Chief Partnerships Officer Glenn Wells gave an opening keynote presentation on the agency’s role in supporting sustainability and Net Zero goals. He discussed: ● British Pharmacopoeia sustainability initiatives ● UK medical device regulation provisions ● the role of MHRA and its place in the UK system for healthcare and sustainability, and ● national and international collaboration.

At the DIA Europe Conference, held in Brussels in mid-March, FDA held a “Townhall” session where Office of the Commissioner (OC) Office of Global Policy and Strategy (OGPS) leaders spoke about the collaboration with EMA and the work of FDA’s foreign offices, including the European Office. Participating in the session were FDA Liaison to the EMA Katherine Tyner, who introduced the session and discussed her role at EMA, and FDA Europe Office staff: ● Director Katie Serrano, who gave an overview of the office ● Deputy Director Shannon Thor, who spoke about the office’s priorities for 2024, and ● Senior Policy Advisor Ioana Ulea, who moderated the Q&A panel discussion and gave a brief summary of the session.